Clinical trials: Controlled Diabetes
Type 1 Diabetes Mellitus
Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas
Subjects will participate in three weeks of the bionic pancreas in the insulin-only configuration. Each week, subjects will use a different rapid acting insulin analog -- Humalog, Novolog, or BC222 insulin lispro -- in a…
- Trial name
- NCT03262116
- Testing
- Humalog, Novolog, BC222 insulin lispro
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus
A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
The purpose of this study is to assess safety of canagliflozin + metformin hydrochloride immediate Release (IR) fixed-dose combination.
- Trial name
- NCT04288778
- Testing
- Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)
- Where
- 10 sites in India
- Volunteers
- 276 people
- Sponsor
- Johnson & Johnson Private Limited
Type 2 Diabetes Mellitus
Sitagliptin Added-on to Insulin Study (0431-051)
A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on insulin or insulin/metformin combination therapy.
- Trial name
- NCT00395343
- Testing
- sitagliptin phosphate
- Volunteers
- 641 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes
Closed-loop Glucose Control for Automated Management of Type 1 Diabetes
We hypothesize that our integrated closed-loop glucose-control system can provide effective, tight, and safe blood glucose (BG) control in type 1 diabetes, thereby establishing the feasibility of closed-loop BG control.
- Trial name
- NCT00811317
- Testing
- Closed-loop
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Boston University Charles River Campus
Diabetes Mellitus, Type 2
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
The primary objective of this study is to compare the effect of albiglutide and exenatide on gastric myoelectrical activity (GMA), gastric emptying (GE) and nausea (as measured by visual analogue scale [VAS]) in subjects with…
- Trial name
- NCT02793154
- Testing
- Exenatide, Albiglutide
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily
This trial is conducted in the United States of America. The aim of this trial is to explore how different fasting blood glucose targets affect glucose control in patients with type 2 diabetes, when patients are empowered to do…
- Trial name
- TITRATE™ (NCT00634842)
- Testing
- insulin detemir
- Where
- 69 sites in United States, Puerto Rico
- Volunteers
- 244 people
- Sponsor
- Novo Nordisk A/S
Diabetic Foot Infections
Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus
Phase I/IIa, five cohort ascending dose with two dosing arms per cohort, study in Type I or II diabetes mellitus subjects with a chronic infected diabetic ulcer defined as having a DUSS score of 0 to 3 and DFI wound score of 1 to…
- Trial name
- NCT02737722
- Testing
- Bisphosphocin Nu-3
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Lakewood-Amedex Inc
Diabetic Nephropathies
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy.
- Trial name
- ARTS-DN (NCT01874431)
- Testing
- Finerenone (BAY94-8862)
- Where
- 147 sites in United States, Australia and 21 more
- Volunteers
- 823 people
- Sponsor
- Bayer
Diabetes
Pilot Project of Health Promotion for People With Diabetes
Limited participation in health promotion activities is noted in people with diabetes, even though lifestyle changes have been found to be essential in decreasing the risk of complications of the disease.
- Trial name
- NCT00970294
- Testing
- Health Promotion Program
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Patricia Kluding, PhD
Diabetic Foot Ulcer
CO2-Laser Treatment in Patients With Diabetic Infected Foot Ulcers
The study is aimed at comparing debridement either with CO2 laser or traditional surgery in patients with infected diabetic foot ulcers. The principal endpoint is bacterial load immediately after treatment.
- Trial name
- DULCIS (NCT02677779)
- Testing
- CO2 laser, traditional surgery
- Volunteers
- 20 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Type 1 Diabetes Mellitus
Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes
This is a double-blind, randomized , placebo-controlled study to evaluate the safety and tolerability of AVT001, and to assess AVT001 as a potential treatment for type 1 diabetes (T1D).
- Trial name
- NCT03895996
- Testing
- AVT001
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Avotres Inc.
Diabetes, Diabetes Mellitus, Type 2
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Africa, Asia, Europe, North America and South America. The purpose is to compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve…
- Trial name
- DUAL™ VIII (NCT02501161)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 143 sites in United States, Argentina and 14 more
- Volunteers
- 1,012 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
B2611003 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 6 treatments for 3 months.
- Trial name
- NCT01338870
- Testing
- 25 mg PF-04991532, 75 mg PF-04991532, 150 mg PF-04991532
- Where
- 42 sites in United States, Canada and 4 more
- Volunteers
- 301 people
- Sponsor
- Pfizer
Diabetic Nephropathy, Type 2 Diabetes Mellitus
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.
- Conditions
- Diabetic Nephropathy, Type 2 Diabetes Mellitus, Proteinuria
- Trial name
- NCT00141453
- Testing
- olmesartan medoxomil
- Where
- 2 sites in China, Japan
- Volunteers
- 577 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetes Mellitus, Chronic Kidney Disease
Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease
This study will assess the effects of vitamin D3 supplementation (cholecalciferol; 2000 IU daily) on serum calcium levels, circulating vitamin D levels, and markers of kidney disease and cardiovascular risk among people with…
- Conditions
- Diabetes Mellitus, Chronic Kidney Disease, Diabetic Kidney Disease
- Trial name
- NCT00552409
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Type 2 Diabetes
Moderate Alcohol Intake Among Patients With Type 2 Diabetes
Our specific aim is to explore the effect of moderate alcohol intake on parameters of glycemic index and lipid profile among patients with type 2 diabetes.
- Trial name
- NCT00295334
- Testing
- alcohol
- Volunteers
- 109 people
- Sponsor
- Iris Shai
Type 2 Diabetes Mellitus
A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a specific metabolite (which is a marker of in vivo…
- Trial name
- NCT00618995
- Testing
- Comparator: ER niacin (+) laropiprant, Comparator: ER niacin, Comparator: laropiprant
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Monotherapy Study of MP-513 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in patients with type 2 Diabetes for 12 weeks administration.
- Trial name
- NCT00998881
- Testing
- Teneligliptin 20 mg
- Where
- Japan
- Volunteers
- 203 people
- Sponsor
- Tanabe Pharma Corporation
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
This study is a Phase II, placebo-controlled, double-blind, randomized trial in 480 participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (for example, diabetes and familial…
- Conditions
- Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
- Trial name
- ORION-1 (NCT02597127)
- Testing
- ALN-PCSSC, Normal Saline
- Where
- 54 sites in United States, Canada and 3 more
- Volunteers
- 501 people
- Sponsor
- The Medicines Company
Type 2 Diabetes Patients
A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in…
- Trial name
- NCT01298518
- Testing
- PF-04620110
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.